Heart attacks rarely happen without warning. They happen because plaque has been quietly building in a coronary artery for years, narrowing the channel that feeds your heart muscle. Max stenosis ramus intermedius (RI) tells you how much narrowing has formed inside one specific branch of your coronary tree, the ramus intermedius, before symptoms appear.
Not every heart has a ramus intermedius. When it is present, it sits between the two largest coronary arteries and feeds part of the left side of the heart muscle. A high stenosis number in this branch reflects the same atherosclerosis (artery-wall plaque buildup) that drives heart attacks elsewhere, and it shows up on imaging long before a routine lipid panel suggests anything is wrong.
Max stenosis ramus intermedius is not a blood test. It comes from a heart imaging study, usually a coronary CT angiogram or invasive coronary angiogram. A radiologist or cardiologist measures the worst point of narrowing along the ramus intermedius and reports it as a percentage. Zero percent means the channel is fully open. Anything above zero means plaque is taking up space inside the artery.
Because the ramus intermedius is a smaller branch than the left anterior descending or left circumflex, plaque here is sometimes treated as less consequential. That framing is misleading. The same biology that narrows this branch is at work throughout your coronary tree, and finding plaque here is a signal about your overall vascular health, not just one vessel.
Stenosis in any coronary branch reflects atherosclerosis, the slow buildup of cholesterol-laden plaque inside artery walls. The clinical case for paying attention to this number rests on a much larger body of work showing that coronary plaque can both grow and shrink in response to treatment. Trials using imaging endpoints have repeatedly shown that aggressive cholesterol lowering can stop plaque progression and, in some cases, partially reverse it.
Very high-intensity statin therapy has produced measurable regression of coronary atherosclerosis on intravascular ultrasound. Adding a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor on top of a statin further increases plaque regression and improves the structure of vulnerable plaque. Comprehensive lifestyle programs combining a low-fat diet, exercise, smoking cessation, and stress management have shown regression of severe coronary atherosclerosis even without lipid-lowering drugs in selected patients. The same biology that drives those changes is what your ramus intermedius number is tracking.
Coronary stenosis is graded by the percentage of the artery's inner channel that plaque is occupying at its worst point. The categories below come from standard angiographic and CT angiographic conventions used across cardiology, not from a single trial population. Different readers and different imaging methods can produce slightly different numbers on the same artery, so use these as orientation, not absolute targets.
| Stenosis Range | Common Label | What It Suggests |
|---|---|---|
| 0% | No visible plaque | No imaging evidence of disease in this branch |
| 1 to 24% | Minimal | Early plaque present, well below flow-limiting |
| 25 to 49% | Mild | Established plaque, generally not flow-limiting |
| 50 to 69% | Moderate | Approaching flow-limiting, often warrants further testing |
| 70 to 99% | Severe | Likely flow-limiting, typically prompts active management |
| 100% | Total occlusion | Branch fully blocked at the lesion |
What this means for you: a result above zero is not a verdict, but it is a signal. Even minimal disease in a single branch is evidence that atherosclerosis is happening in your body, which means the same process is likely underway in arteries that were not directly imaged. The earlier you know, the more time you have to act.
A single stenosis percentage is a snapshot. What matters more is the trajectory: is the plaque growing, holding steady, or regressing? Coronary imaging trials show that plaque burden can change measurably within months of starting intensive treatment. A repeat scan at the right interval lets you see whether your prevention plan is actually working on the artery wall, not just on your blood numbers.
A reasonable approach is a baseline coronary CT angiogram if you have risk factors or a family history of early heart disease, with follow-up imaging timed to your clinical situation. For many people that means rescanning every two to five years, sooner if you have made major changes to medication or lifestyle and want to know if the plaque is responding. Within-reader and within-scanner variability matters here, so getting follow-up imaging at the same center using the same protocol gives you a more reliable trend.
Stenosis measurements can be affected by factors that have nothing to do with how much plaque you actually have.
Plaque in the ramus intermedius rarely sits alone. If a stenosis is present in this branch, the rest of the imaging report matters: are there lesions elsewhere, how much calcium is there, and what does the overall plaque burden look like? A complete coronary CT angiogram already gives you that information. Pair the imaging with a full vascular workup: ApoB (apolipoprotein B, which counts every plaque-forming cholesterol particle), Lp(a) (lipoprotein little a, an inherited heart attack risk marker), hs-CRP (high-sensitivity C-reactive protein, a marker of vascular inflammation), and a fasting metabolic panel.
Moderate or severe stenosis warrants involvement of a cardiologist, ideally one focused on prevention or a lipidologist. They can decide whether functional testing (stress testing or fractional flow reserve) is needed to know if a lesion is limiting blood flow, and whether more intensive lipid-lowering, blood pressure control, or other therapies are appropriate. Even minimal or mild stenosis in someone under 60 is reason to treat your prevention plan as urgent rather than optional.
Evidence-backed interventions that affect your Max Stenosis Ramus Intermedius level
Max Stenosis Ramus Intermedius is best interpreted alongside these tests.